Sugi Predict

Sugi Predict / Compounds / SCHEMBL1267993

SCHEMBL1267993

SCHEMBL1267993

FC(F)(F)c1ccccc1CNc1ccc(Cc2c[nH]c3ncccc23)cn1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 4/20 0.74
▸ KIT P10721 3/20 0.74
▸ CYP3A4 P08684 9/20 0.64
▸ CYP2C19 P33261 5/20 0.64
▸ CDC7 O00311 1/20 0.55
▸ MAP4K4 O95819 1/20 0.55
▸ PIM1 P11309 1/20 0.55
▸ PRKACA P17612 1/20 0.55
▸ CDK2 P24941 1/20 0.55
▸ GSK3B P49841 1/20 0.55
▸ HIPK2 Q9H2X6 1/20 0.55
▸ MKNK2 Q9HBH9 1/20 0.55
▸ IRAK4 Q9NWZ3 1/20 0.55
▸ LCK P06239 1/20 0.52
▸ PGR P06401 1/20 0.52
▸ CHRM2 P08172 1/20 0.52
▸ HTR1A P08908 1/20 0.52
▸ ADRA2A P08913 1/20 0.52
▸ PDGFRB P09619 1/20 0.52
▸ ADORA3 P0DMS8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1267681 0.91 CSF1R (0.71) CSF1RKITCYP3A4CYP2C19CDC7
SCHEMBL1888029 0.91 CYP3A4 (0.76) CSF1RKITCYP3A4CYP2C19CDC7
SCHEMBL1267721 0.90 CSF1R (0.69) CSF1RKITCYP3A4CYP2C19CDC7
SCHEMBL1266739 0.89 CDC7 (0.60) CSF1RKITCYP3A4CYP2C19CDC7
SCHEMBL1268221 0.88 CSF1R (0.69) CSF1RKITCYP3A4CYP2C19CDC7
SCHEMBL1267733 0.88 CSF1R (0.69) CSF1RKITCYP3A4CYP2C19CDC7
SCHEMBL27975238 0.87 CSF1R (0.64) CSF1RKITCYP3A4CYP2C19CDC7
SCHEMBL1267559 0.86 CSF1R (0.69) CSF1RKITCYP3A4CYP2C19CDC7
SCHEMBL1266824 0.86 CSF1R (0.69) CSF1RKITCYP3A4CYP2C19CDC7
SCHEMBL1267608 0.86 CSF1R (0.69) CSF1RKITCYP3A4CYP2C19CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130274259-A1 KINASE MODULATION AND INDICATIONS THEREFOR DAIICHI SANKYO, INC. 2013-10-17 — — US claimed
CN-101605787-A Compounds that modulate c-fms and/or c-kit activity and uses thereof PLEXXIKON INC (US) 2009-12-16 — — CN claimed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 — — US claimed
WO-2008064265-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO claimed
EP-4295912-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Daiichi Sankyo, Inc. (US) 2023-12-27 — — EP disclosed
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 — — US disclosed
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 — — US disclosed
US-10123998-B2 Kinase modulation, and indications therefor PLEXXIKON INC. (US) 2018-11-13 — — US disclosed
US-20180055828-A1 KINASE MODULATION, AND INDICATIONS THEREFOR DAIICHI SANKYO, INC. 2018-03-01 — — US disclosed
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 — — US disclosed
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 — — US disclosed
US-9730918-B2 Kinase modulation, and indications therefor PLEXXIKON INC. (US) 2017-08-15 — — US disclosed
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 — — US disclosed
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 — — US disclosed
CN-101605787-A Compounds that modulate c-fms and/or c-kit activity and uses thereof PLEXXIKON INC (US) 2009-12-16 — — CN disclosed
EP-2086972-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2009-08-12 — — EP disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 — — US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 — — US disclosed
WO-2008064255-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed
WO-2008064265-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10123998-B2 Kinase modulation, and indications therefor FLT3, FLT4, FLT1 CSF1R 147/4885KIT 33/4885CYP3A4 4236/4885
US-20130274259-A1 KINASE MODULATION AND INDICATIONS THEREFOR FLT3, MET, BTK CSF1R 33/4885KIT 138/4885CYP3A4 4525/4885
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885CYP3A4 3847/4885
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885CYP3A4 3847/4885
US-20180055828-A1 KINASE MODULATION, AND INDICATIONS THEREFOR FLT3, FLT4, FLT1 CSF1R 147/4885KIT 33/4885CYP3A4 4236/4885
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885CYP3A4 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.